1. Inclusion of drugs in provincial drug benefit programs: should “reasonable” decisions lead to uncontrolled growth in expenditures;Gafni;CMAJ,2003
2. Cost-Effectiveness in Health and Medicine,1996
3. Economic benefit analysis of primary prevention with pravastatin. Assumptions are methodologically flawed;Freemantle;BMJ,1998
4. Letter to the Editor;Caro;BMJ,1998
5. Cost-effectiveness analysis: are the outputs worth the inputs?;Naylor;ACP J Club,2000